



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number AREX-P03-004

Complete If Known

Application Number	09/376,604
Filing Date	August 18, 1999
First Named Inventor	Ragupathy Madiyalakan
Art Unit	1642
Examiner Name	G. B. Nickol

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
KAC	AE	US-4,740,371	04-26-1988	St. Remy et al.	
	AF	US-4,879,225	11-07-1989	Morgan Jr. et al.	
	AG	US-5,512,283	04-30-1996	Byers et al.	
	AH	US-5,583,202	12-10-1996	Zanetti	
	AI	US-5,591,593	01-07-1997	Courtenay-Luck	
	AJ	US-5,652,114	07-29-1997	Chu et al.	
	AK	US-5,688,657	11-18-1997	Tsang et al.	
	AL	US-5,869,445	02-09-1999	Cheever et al.	
	AM	US-6,068,830	05-30-2000	Diamandis et al.	
	AN	US-6,077,519	06-20-2000	Storkus et al.	
	AO	US-6,140,091	10-31-2000	Raso et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)	MM-DD-YYYY		
					1 ⁸

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
KAC	CP	Chattopadhyay et al., "Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1," <i>Cancer Res.</i> , 5:6045-51 (1991).			1 ⁸
KAC	CQ	Clark, "Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), <i>Prot. Eng.</i> , 1 (1993).			
KAC	CR	Crowley et al., "Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins", <i>J. Exp. Med.</i> , 172:383-386 (1990).			
KAC	CS	De la Salle, "Fc _Y R on Human Dendritic Cells", <i>Human IgG Receptors</i> , p. 39-55 (1996).			
KAC	CT	Fagerberg, "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A," <i>Cancer Imm.</i> , 12:81-87 (1996).			
KAC	CU	Frodin et al., Hybridoma, "Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome—an important antitumoral effector function?", 10:421-31 (1991).			
KAC	CV	Goldenberg et al., "Cancer Diagnosis and Therapy with Radiolabeled Antibodies", In: <i>Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer</i> , Vogel, Ed., 259-280 (1987).			
KAC	CW	Keder et al., "Cancer Immunotherapy: Are the results discouraging? Can they be improved?", <i>Adv. Cancer Res.</i> , 59:245-323 (1992).			

Examiner Signature 3109665	/Karen A. Canella, Ph.D./	Date Considered	08/07/2006
-------------------------------	---------------------------	-----------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	09/376,604
Sheet	2	of	2	Filing Date	August 18, 1999
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1642
				Examiner Name	G. B. Nickol
				Attorney Docket Number	AREX-P03-004

KAC	CX	Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes," Nature, 272:265-66 (1978).	
KAC	CY	McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993).	
KAC	CZ	Paul, "Factors limiting effective tumor immunity", Fund. Imm., 1163-69 (1993).	
KAC	CA1	Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993).	
KAC	CB1	Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α ," J. Exp. Med., 179:1109-1118 (1994).	
KAC	CC1	Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991).	
KAC	CD1	Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 th Ed., 531-542 (1994).	
KAC	CE1	Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab')2 fragments," Imm. Letts., 27:39-44 (1991).	
KAC	CF1	Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997).	
KAC	CG1	Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65:406-412 (1996).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	/Karen A. Canella, Ph.
--------------------	---------------------------	-----------------	------------------------

3199685